What's in Danish Headache Center's pipeline?

Danish Headache Center has 17 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 15 in Phase 1.

Which companies overlap with Danish Headache Center's portfolio?

Top competitors by shared drug class: The University of Texas Medical Branch, Galveston.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/danish-headache-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Danish Headache Center — Portfolio Competitive Intelligence Brief

Danish Headache Center pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Calcitonin Gene-Related Peptide	Calcitonin Gene-Related Peptide	marketed
VIP	VIP	marketed	Neuropeptide agonist	VIP receptor (VPAC1/VPAC2)	Neurology

Therapeutic area mix

Other · 3
Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

The University of Texas Medical Branch, Galveston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Danish Headache Center:

Cite this brief

Drug Landscape (2026). Danish Headache Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/danish-headache-center. Accessed 2026-05-16.